-
A Major Milestone: Lilly’s Olomorasib Receives FDA Breakthrough Therapy Designation
NYSE: $LLY New Hope for KRAS G12C Patients The landscape of cancer research is shifting as Eli Lilly and Company announces that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to olomorasib. This investigational oral therapy is being developed as a potential treatment for patients with previously treated KRAS G12C-mutated non-small…
-
A New Frontier in Lung Cancer Treatment: HARMONI Phase III Results for Ivonescimab
NASDAQ: $SMMT A Breakthrough in Oncology Recent findings published in The Lancet have shed light on the promising results of the HARMONI Phase III clinical trial. The study evaluates the efficacy and safety of ivonescimab, a novel bispecific antibody, when combined with chemotherapy for the treatment of patients with locally advanced or metastatic non-squamous non-small…
-
Advancing Lung Cancer Treatment: Insights from the EVOLVE-Lung02 Phase III Trial
A New Frontier in Non-Small Cell Lung Cancer Therapy Recent developments in oncology have brought forward promising data from the EVOLVE-Lung02 Phase III clinical trial. This study is evaluating the efficacy of volrustomig, a novel bispecific antibody, when combined with standard chemotherapy for patients diagnosed with metastatic non-small cell lung cancer (NSCLC). Understanding the Research…